Takeda Taps Ultragenyx To Step Up Rare Disease Efforts
This article was originally published in PharmAsia News
Executive Summary
In its second deal in recent days, Takeda is moving more decisively into the rare disease space through a licensing and collaborative R&D alliance with the specialist US firm Ultragenyx.